NCT02807974View on ClinicalTrials.gov

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

PHASE3CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Hypertension
Interventions
DRUG

CS-3150

CS-3150 1.25 to 2.5, 5mg, orally

Trial Locations (1)

Unknown

Sanuki-shi

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY